Chordia Therapeutics Inc.  
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan  
info@chordiatherapeutics.com

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
12.12 2022

Chordia Therapeutics Announces Interim Results from the Phase I Clinical Trial and the Non-clinical Study of CLK Inhibitor CTX-712 and the Results from the Non-clinical Study of MALT-1 Inhibitor CTX-177 Presented at the 2022 ASH Annual Meeting.

Kanagawa, Japan, December 12, 2022 – Chordia Therapeutics Inc. (“Chordia”), a biotech company engaged in the research and development of novel therapies for cancers, today announced that it presented the interim results from the Phase I clinical trial and the non-clinical study of CTX-712, a selective pan-CDC-like kinase (“CLK”) inhibitor and the results from the non-clinical study of CTX-177 (ONO-7018), MALT-1 inhibitor, at the 64th Annual Meeting of the American Society of Hematology (ASH) being held from December 10 to December 13.

In a cohort of patients with hematologic cancers in the Phase 1 clinical trial of CTX-712, four complete remission (CR) and one complete remission with neutrophil failure (CRi) were observed in eight patients with acute myeloid leukemia and myelodysplastic syndrome. This confirmed the POC (Proof of Concept) of the clinical trial. A dose-dependent increase in systemic exposure was observed in pharmacokinetics (PK) analysis, and a dose-dependent increase in exon skipping of RNAs used as pharmacodynamics (PD) markers confirmed mRNA splicing modification by CTX-712. Further studies are currently underway to determine the recommended Phase 2 dosing.

“It is a great honor to be involved in the first-in-human clinical trial of a new anticancer drug with a novel mechanism of action,” said Dr. Hisayuki Yokoyama, Associate Professor of Hematology at Tohoku University Hospital and lead author of this presentation. “Although it is still in the early stage of clinical trials, we are pleased that more than half of the patients with hematologic malignancy showed remission in the clinical trial. We hope that CTX-712 will become an effective treatment for patients with advanced, relapsed, or refractory malignancies in the future.”

ASH abstract number: 2763
Title: A First-in-Human Phase I Study of CTX-712 in Patients with Advanced, Relapsed or Refractory Malignant Tumors - Hematologic Malignancies Dose Escalation Cohort

The following are the abstract numbers of the announcement made by the Company and its collaborators regarding the pre-clinical studies of CTX-712 and CTX-177 (ONO-7018).
ASH abstract number: 202
Title: CTX-712, a Novel Splicing Modulator Targeting Myeloid Neoplasms

ASH abstract number: 4000
Title: Preclinical Translational Research Suggests a Clinical Trial Strategy for a Novel MALT1 Inhibitor ONO-7018/CTX-177 Against Malignant Lymphomas

About CTX-712
CTX-712 is a first-in-class, orally available and selective small molecule inhibitor of CLK, a key regulator of the RNA splicing process that plays an important role in cell growth. CTX-712 inhibits the growth of various human tumor cell lines in vitro and, in addition, exhibits antitumor activity in multiple xenograft mouse models in vivo.

Details of Phase 1 Clinical Trial
The Phase 1 clinical trial in Japan is investigating the tolerability, safety, and pharmacokinetics (PK) of CTX-712 in patients with advanced, relapsed, or refractory malignancies. For details of the study, please refer to JapicCTI-184188.

About RNA Splicing
RNA immediately after transcription is called precursor messenger RNA which contains noncoding sequences (introns) as well as coding sequences (exons) that are needed to make proteins. RNA splicing is a process to remove the introns and connect the exons to form mature mRNA, which is then translated into protein.

About CDC-like Kinases (CLKs)
Kinase is a general term for enzymes that catalyze the transfer of phosphate groups in biological substances, such as ATP, over to target substances that are called substrates. Over 500 protein kinases are known in humans, of which the CLK family consists of four members – CLK1, CLK2, CLK3, and CLK4, and phosphorylates serine/arginine-rich (SR) proteins as substrates.

About Exon Skipping
When CTX-712 inhibits CLK kinases and the SR protein dephosphorylates, a splicing change called exon skipping occurs, in which the exons fail to be incorporated into the mature mRNA.

About CTX-177 (ONO-7018)
CTX-177 (ONO-7018) is a selective inhibitor against a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), which is known to be involved in intracellular signaling pathway in lymphocytic blood cells. Activation of MALT1 is reported to play an important role in malignancies of lymphocytes. CTX-177 (ONO-7018) is expected to exert anti-tumor effect against these malignancies by inhibiting MALT1 activity. CTX-177 (ONO-7018) is in Phase 1 study in the United States by our licensing partner, Ono Pharmaceutical Co., Ltd. For more information, please visit the following website at clinicaltrials.gov/ (NCT05515406).
Important Notice
In this press release, the definition of “press release” covers any oral presentation, question and answer session, and written and/or oral materials discussed or distributed by Chordia Therapeutics in connection with this press release. This press release (including the oral description and related questions and answers) is not intended to constitute, represent, or form part of any offer, invitation, or solicitation to purchase and/or acquire anything, including securities.

Disclaimer
Any announcements by Chordia Therapeutics, including this press release, may contain information on products derived from pharmaceutical developments, but are intended to inform the latest information related to Chordia’s business, and not intended as promotions, solicitations, advertisements, or to provide medical advice.

Forward-Looking Statements
This press release and materials distributed in connection with this press release may contain forward-looking statements, information, beliefs, and opinions concerning our future operations, future positioning, and performance, including estimates, projections, goals, and plans. Forward-looking statements may include, but are not limited to, expressions such as "goals," "plans," "beliefs," "hopes," "continues," "expects," "intends," "assures," "will," "may," "should," "would," "could," "estimates," "projects," and/or other similar expressions, or the negative thereof. These forward-looking statements are based on assumptions concerning a number of important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements; highly influential factors that include economic conditions surrounding our global business, which include general economic conditions in Japan and the United States, competitive pressures and developments including changes in applicable laws and regulations, which include global healthcare reform, uncertainty as to our clinical success, and challenges inherent in new product development (which include regulatory decisions and their timing,) uncertainty as to the commercial success of new and existing products manufacturing difficulties, delays fluctuations in interest rates and exchange rates claims or concerns regarding the safety or efficacy of commercial products or product candidates the impact of a health crisis, such as the COVID-19 pandemic, on Chordia and its customers and suppliers (including foreign governments in countries in which the Company conducts business) or other aspects of its business. We undertake no obligation to update any forward-looking statements contained in this press release or any other forward-looking statements we may make, except as required by law or stock exchange rules. Past performance is not indicative of future operating results, and any of our operating results or statements in this press release are not estimates, forecasts, warranties, or projections of our future operating results.

About Chordia Therapeutics
Chordia was established in November 2017 at Shonan Health Innovation Park (“Shonan iPark”) in Fujisawa, Kanagawa Prefecture, as a biotech company engaged in the research and development of novel therapies for cancers, with the goal of
researching and developing first-in-class anti-cancer drugs and creating innovative new drugs. In addition to its leading program for CTX-712, Chordia is engaged in the research of several developments in our pipeline, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Representative: Hiroshi Miyake, Representative Director
Website: https://www.chordiatherapeutics.com/en/

For more information, please contact IR: info@chordiatherapeutics.com